These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6723482)

  • 1. Irritative properties of two clinical potassium chloride formulations on duodenal mucosa of the cat and esophageal mucosa of the opossum.
    Alphin RS; O'Dell SW; Sancilio LF; Ward JW
    Dig Dis Sci; 1984 Jun; 29(6):508-12. PubMed ID: 6723482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of five potassium chloride preparations on the upper gastrointestinal mucosa in healthy subjects receiving glycopyrrolate.
    Alsop WR; Moore JG; Rollins DE; Tolman KG
    J Clin Pharmacol; 1984; 24(5-6):235-9. PubMed ID: 6747020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo.
    Sinar DR; Bozymski EM; Blackshear JL
    Clin Ther; 1986; 8(2):157-63. PubMed ID: 3698061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment and validation of animal models to evaluate topical effects of substances on gastrointestinal mucosa.
    Fara JW; Anderson LD; Casper AG; Myrback RE
    Pharm Res; 1988 Mar; 5(3):165-71. PubMed ID: 3244628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and dosage form design in drug-induced topical irritation of the gastrointestinal tract.
    Fara JW; Myrback RE
    Pharm Res; 1990 Jun; 7(6):616-20. PubMed ID: 2102665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations.
    Graham DY; Smith JL; Bouvet AA
    J Pharm Sci; 1990 May; 79(5):420-4. PubMed ID: 2352162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline.
    Bronson DL; Gamelli RL
    J Clin Pharmacol; 1987 Oct; 27(10):788-9. PubMed ID: 3429685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.
    McMahon FG; Ryan JR; Akdamar K; Ertan A
    Lancet; 1982 Nov; 2(8307):1059-61. PubMed ID: 6127542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of potassium chloride supplements on upper gastrointestinal mucosa.
    McMahon FG; Ryan JR; Akdamar K; Ertan A
    Clin Pharmacol Ther; 1984 Jun; 35(6):852-5. PubMed ID: 6734038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal irritant potential of a potassium-sparing diuretic and of wax-matrix potassium chloride.
    Ryan JR; McMahon FG; Akdamar K; Ertan A; Agrawal N
    Clin Pharmacol Ther; 1984 Jan; 35(1):90-3. PubMed ID: 6690174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopic comparison of solid and liquid potassium chloride supplements.
    Patterson DJ; Weinstein GS; Jeffries GH
    Lancet; 1983 Nov; 2(8358):1077-8. PubMed ID: 6138615
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioavailability and pharmacokinetics of a new, slow-release potassium chloride capsule.
    Arnold J; Jacob JT; Riley B
    J Pharm Sci; 1980 Dec; 69(12):1416-8. PubMed ID: 7463329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability and pharmacokinetics of a new sustained-release potassium chloride tablet.
    Betlach CJ; Arnold JD; Frost RW; Leese PT; Gonzalez MA
    Pharm Res; 1987 Oct; 4(5):409-11. PubMed ID: 3508550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment.
    Moore JG; Alsop WR; Freston JW; Tolman KG
    Gastrointest Endosc; 1986 Jun; 32(3):210-2. PubMed ID: 3522347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ulceration of the small intestine due to slow-release potassium chloride tablets.
    Leijonmarck CE; Räf L
    Acta Chir Scand; 1985; 151(3):273-8. PubMed ID: 4013604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potassium chloride preparations and fecal blood loss. A parallel study with a 10 percent solution and a non-enteric-coated waxy-matrix tablet.
    Rider JA; Manner RJ; Swader JI
    JAMA; 1975 Feb; 231(8):836-7. PubMed ID: 1172753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of stenotic obstruction of the jejunum secondary to slow-release potassium.
    Barloon TJ; Moore SA; Mitros FA
    Am J Gastroenterol; 1986 Mar; 81(3):192-4. PubMed ID: 3953535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and effects on fecal blood loss of a controlled release potassium chloride tablet.
    Tannen RL; Cordano A
    J Pharmacol Exp Ther; 1978 Jan; 204(1):240-6. PubMed ID: 304099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss.
    Lech Y; Hey H; Jørgensen F; Matzen P; Ostergaard O
    J Clin Pharmacol; 1987 Mar; 27(3):206-9. PubMed ID: 3680575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations.
    Strom BL; Carson JL; Schinnar R; Sim E; Maislin G; Soper K; Morse ML
    Arch Intern Med; 1987 May; 147(5):954-7. PubMed ID: 3495244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.